APA (7th ed.) Citation

E, L., M, H., J, Q., ML, G., J, V., J, B., . . . CD, F. (2026). Nonmyeloablative pentostatin-cyclophosphamide preconditioning improves rates of engraftment in adults undergoing haploidentical HCT for sickle cell disease. PloS one, 21(3), e0332282. https://doi.org/10.1371/journal.pone.0332282

Chicago Style (17th ed.) Citation

E, Limerick, Hsieh M, Queen J, Grecco ML, Varga J, Brooks J, Coles W, Jeffries N, and Fitzhugh CD. "Nonmyeloablative Pentostatin-cyclophosphamide Preconditioning Improves Rates of Engraftment in Adults Undergoing Haploidentical HCT for Sickle Cell Disease." PloS One 21, no. 3 (2026): e0332282. https://doi.org/10.1371/journal.pone.0332282.

MLA (9th ed.) Citation

E, Limerick, et al. "Nonmyeloablative Pentostatin-cyclophosphamide Preconditioning Improves Rates of Engraftment in Adults Undergoing Haploidentical HCT for Sickle Cell Disease." PloS One, vol. 21, no. 3, 2026, p. e0332282, https://doi.org/10.1371/journal.pone.0332282.